Eli Lilly and Company Receivables

Eli Lilly and Company's receivables stands at $23B as of June 2026. That compares with $17B in the prior-year period — up 36.4% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Eli Lilly and Company reported $23B in receivables versus $17B a year earlier — a 36.4% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $17B in the prior-year period — up 36.4% year over year. Sustained growth in receivables can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Eli Lilly and Company's receivables evolved across reporting periods, while the comparison chart places LLY.DE next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, receivables is commonly used to spot outliers. Eli Lilly and Company's reading of $23B is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.